Otoacoustic Emissions in Different Blood Types

Hearing Loss, Cochlear Clinical Trial

Official title:

The Association of Blood Type Differences and Signal-Noise Ratio in TEOAE and DPAOE in Individuals With Normal Hearing

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06326866
• Other study ID #: E-74555795-050.04-941208
• Status: Completed
• Start date: February 7, 2024
• Est. completion date: March 18, 2024

Study information

• Verified date: March 2024
• Source: Istanbul University - Cerrahpasa (IUC)
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The objective of this study is to examine whether ABO and Rhesus (Rh) blood group systems have an association with distortion product otoacoustic emission (DPOAE) and transient otoacoustic emission (TEOAE) amplitudes with the hypothesis of blood groups may affect hearing thresholds.

Description:

Many factors have a significant impact on otoacoustic emission (OAE) measurement and quality of analysis. Race, age and gender are among the non-pathological factors. To date there is clear data to demonstrate the association of blood types with OAEs. The aim of our research is to investigate the relation of different blood groups (ABO) and Rh factors on transient evoked OAE and distortion product OAE amplitudes and inner ear potentials, differences between ears and to contribute to the limited literature on cochlear hearing loss susceptibility and blood groups with the hypothesis that blood groups may be associated with hearing thresholds.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 70
• Est. completion date: March 18, 2024
• Est. primary completion date: March 12, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 26 Years

Eligibility

Inclusion Criteria:

• not having hearing loss
• having a blood group card obtained from health institutions

Exclusion Criteria:

• not meeting inclusion criteria

Related Conditions & MeSH terms

• Hearing Loss
• Hearing Loss, Cochlear
• Hearing Loss, Sensorineural

Intervention

Diagnostic Test:
• Otoacoustic emissions (non-invasive)
There is no invasive intervention in the study. Individuals with predetermined blood types will be included in the study.

Locations

Country	Name	City	State
Turkey	Eyyup KARA	Istanbul

Sponsors (1)

Lead Sponsor	Collaborator
Istanbul University - Cerrahpasa (IUC)

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Signal to noise ratios	SNRs obtained for different frequencies in OAE In TEOAE, 1, 1.4, 2, 2.8, 4 kHz, in DPOAE 1, 1.4, 2, 2.8, 4, 6 kHz	1 month